Recent News for BLRX - BioLineRx Ltd.

Date Title
Jun 1 BioLineRx slips 14% on launch of $4.4M direct offering
Jun 1 BioLineRx Announces $4.39 Million Registered Direct Offering
May 29 Top Ranked Momentum Stocks to Buy for May 29th
May 27 3 “Strong Buy” Biotech Stocks Under $5 With Explosive Upside Potential
May 27 BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine
May 26 Mid-Afternoon Market Update: Crude Oil Up 2%; argenx Shares Spike Higher
May 26 BioLineRx down 29% on launch of $9M direct offering
May 26 BioLineRx Announces $9.0 Million Registered Direct Offering
May 20 BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2020 Results - Earnings Call Transcript
May 20 biolinerx EPS beats by $0.78
May 20 BioLineRx Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 15 BioLineRx to Report First Quarter 2020 Results on May 20, 2020
Apr 7 BioLineRx up big ahead of key data readout
Mar 12 BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q4 2019 Results - Earnings Call Transcript
Mar 12 BioLineRx Ltd. to Host Earnings Call
Mar 12 biolinerx EPS beats by $2.14
Mar 12 BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update
Mar 6 BioLineRx to Report Annual 2019 Results on March 12, 2020
Feb 27 BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination With Anti-PD-1 for the Treatment of Any Type of Cancer
Jan 23 BioLineRx Concludes Recruitment in Pancreatic Cancer Study
Jan 22 BioLineRx completes enrollment in mid-stage BL-8040 study
Jan 22 9 Healthcare Stocks Moving In Wednesday's Pre-Market Session
Jan 22 6 Biotechnology Stocks Moving In Wednesday's Pre-Market Session
Jan 22 BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients With Second-line Metastatic Pancreatic Cancer
Jan 21 How To Play BioLineRx In 2020

Back to the Main BLRX Page...